Adjuvant therapy in prostate cancer: Patient identification and treatment options

S. Syed, A. Tolcher, D. Troyer, J. Furman, R. Leach, I. M. Thompson

Research output: Contribution to journalReview articlepeer-review

Abstract

The recent downward shift in disease stage and patient age at diagnosis has led to an emphasis on definitive local therapy in patients with prostate cancer. However, patients with adverse prognostic factors (non-organ-confined disease, high prostate-specific antigen level, high Gleason score) have a significant risk of treatment failure. With our increasing ability to predict patients at high risk of failure, more patients are likely to receive adjuvant therapy. Adjuvant hormonal therapy extends overall survival after radiotherapy for locally advanced disease, while after surgery improved survival has been demonstrated in patients with node-positive disease. More recently, adjuvant chemotherapy has been investigated.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalUroOncology
Volume4
Issue number3-4
DOIs
StatePublished - Sep 1 2004

Keywords

  • Adjuvant therapy
  • Antiandrogens
  • GnRH agonists
  • Hormonal therapy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adjuvant therapy in prostate cancer: Patient identification and treatment options'. Together they form a unique fingerprint.

Cite this